BioSpace News Archive

California based Best Chance Products, LLC announced that BioCore Co., Ltd., a South Korean manufacturer of 2019 nCoV Real Time PCR Test Kits, has named it the exclusive distributor of BioCore’s COVID-19 Tests in the United States.

Transparency Market Research has published a new report on the plantar fasciitis treatment market for the forecast period of 2019–2027.

The vendor landscape of the global market of hematology diagnostics features a handful of companies collectively accounting for a large share in the overall market, hinting at a largely consolidated vendor landscape, observes Transparency Market Research in a recent report.

Tiziana Life Sciences plc announces that it intends to demerge its StemPrintER and SPARE genomics-based personalized medicine businesses into a separate company and effect a capital reduction to facilitate the spin-out and listing of StemPrintER as an independent entity.

Teva Pharmaceutical Industries Ltd. announced that new data on AJOVY® and the burden of migraine in Europe will be presented at the 6th Congress of the European Academy of Neurology, being held virtually from 23-26 May 2020.

Clinical Laserthermia Systems AB announced it is conducting new in-vivo precision laser ablation treatment studies for neuro and prostate using its TRANBERG Thermal Therapy System with Thermoguide thermometry software.

Ra Medical Systems, Inc. announced receipt of written notice from The New York Stock Exchange indicating that Ra Medical is no longer in compliance with the NYSE’s continued listing standards as set forth in Section 802.01C of the NYSE’s Listed Company Manual, which requires listed companies to maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period.

ORLANDO, Fla., May 22, 2020 (GLOBE NEWSWIRE) -- Breaking news last night commemorates a very important step for medical technology company Biotricity (OTCQB: BTCY) . For our many readers following the Company and its investors, today is significant. What is coming for Biotricity is a binary event that could change its future dramatically. Here’s what you need to know. Today, Biotricity reported that it recently received correspondence from the FDA

OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced that its OMNIgene®·ORAL saliva collection device was included in the U.S. Food and Drug Administration Emergency Use Authorization granted to P23 Labs.

The Company’s New & Improved E-Commerce Website (www.taurigum.com) Includes the Following Features: Customer Reward(s) Program, Subscription Model, Gift Cards, and Real-Time Reviews